Survival improvement of AIDS-related progressive multifocal leukoencephalopathy in the era of protease inhibitors

AIDS

Volumn 13, Issue 14, 1999, Pages 1881-1887

  Tassie, Jean Michel ^a   Gasnault, Jacques ^b   Bentata, Michèle ^c   Deloumeaux, Jacqueline ^a   Boué, François ^d   Billaud, Eric ^e   Costagliola, Dominique ^a  

^a INSERM   (France)

^b BICÊTRE HOSPITAL   (France)

^c AVICENNE HOSPITAL   (France)

^d HÔPITAL ANTOINE BÉCLÈRE   (France)

^e HÔTEL DIEU   (France)

Author keywords

Cohort study; HIV; Progressive multifocal leukoencephalopathy; Protease inhibitor; Survival

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; COHORT ANALYSIS; DATA BASE; FEMALE; FRANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROBABILITY; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RISK; SURVIVAL;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; FEMALE; FOLLOW-UP STUDIES; HIV PROTEASE INHIBITORS; HUMANS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MALE; PROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS;

EID: 0032708732     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199910010-00010     Document Type: Article

References (31)

1. Brooks BR, Walker DL. Progressive multifocal leukoencephalopathy. Neurol Clin 1984, 2:299-313.
2. Miller J, Barrett R, Britton C. Progressive multifocal leukoencephalopathy in a male homosexual with T-cell immune deficiency. N Engl J Med 1982, 307:1436-1438.
3. Holman RC, Torok TJ, Belay ED, Janssen RS. Progressive multifocal leukoencephalopathy in the United States, 1979-1994 increased mortality associated with HIV infection. Neuroepidemiology 1998, 17:303-309.
4. Krupp LB, Lipton RB, Swerdlow ML, Leeds NE, Llena J. Progressive multifocal leukoencephalopathy. clinical and radiographic features. Ann Neurol 1985, 17:344-349.
5. Gillepsie SM, Chang Y, Lemp C, et al. Progressive multifocal leukoencephalopathy in persons infected with the immunodeficiency virus, San Francisco 1981-1989. Ann Neurol 1991, 30:597-604.
6. Berger JR, Concha M. Progressive multifocal leukoencephalopathy. the evolution of a disease once considered rare. J Neurovirol 1995, 1:5-18.
7. Fong IW, Toma E, and the Canadian PML study group. The natural history of progressive multifocal leukoencephalopathy. Clin Infect Dis 1995, 20:1305-1310.
8. Gasnault J, Taoufik Y, Goujard C, et al. Prolonged survival without neurological improvement in patients with AIDS-related progressive multifocal leukoencephalopathy on potent combined antiretroviral therapy. J Neurovirol 1999, (in press).
9. Power C, Nath A, Aoki FY, Del Bigio M. Remission of progressive multifocal leukoencephalopathy following splenectomy and antiretroviral therapy in a patient with HIV infection. N Engl J Med 1997, 336:661-662.
10. Elliot B, Aromin I, Gold R, Flanigan T, Mileno M. 2.5 year remission of AIDS-associated progressive multifocal leukoencephalopathy with combined antiretroviral therapy [letter]. Lancet 1997, 349:850.
11. Domingo P, Guardiola JM, Iranzo A, Margall N. Remission of progressive multifocal leukoencephalopathy after antiretroviral therapy. Lancet 1997, 349:1554-1555.
12. Baqi M, Kucharczyk W, Walmsley SI. Regression of progressive multifocal leukoencephalopathy with highly active antiretroviral therapy [letter]. AIDS 1997, 11:1526-1527.
13. Albrecht H, Hoffmann C, Degen O, et al. Highly active antiretroviral therapy significantly improves the prognosis of patients with HIV-associated progressive multifocal leukoencephalopathy. AIDS 1998, 12:1149-1154.
14. Cinque P, Casari S, Bertelli D. Progressive multifocal leukoencephalopathy, HIV and highly active antiretroviral therapy. N Engl J Med 1998, 339:848-849.
15. Miralles P, Berenguer J, Garcia de Viedma D, et al. Treatment of AIDS-associated progressive multifocal leukoencephalopathy with highly active antiretroviral therapy. AIDS 1998, 12:2467-2472.
16. Clifford DB, Yiannoutsos C, Glicksman M, et al. HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathy. Neurology 1999, 52:623-625.
17. Berger JR, Pall L, Lanska D, Whiteman M. Progressive multifocal leukoencephalopathy in patients with HIV infection. J Neurovirol 1998, 4:59-68.
18. Weber T, Frye S, Bodemer M, Otto M, Luke W. Clinical implications of nucleic acid amplification methods for the diagnosis of viral infections of the nervous system. J Neurovirol 1996, 2:175-190.
19. Cinque P, Scarpellini P, Vago L, Linde A, Lazzarin A. Diagnosis of central nervous system complications in HIV-infected patients, cerebrospinal fluid analysis by polymerase chain reaction. AIDS 1997, 11:1-17.
20. Munoz A, Sabin CA, Phillips AN. The incubation period of AIDS. AIDS 1997, 11 Suppl. A:S69-S76.
21. Glesby MJ, Hoover DR. Survivor treatment selection bias in observational studies, examples from the AIDS literature. Ann Intern Med 1996, 124:999-1005.
22. Egger M, Hirschel B, Francioli P, et al. Impact of new antiretroviral combination therapies in HIV-infected patients in Switzerland: prospective multicentre study. BMJ 1997, 315:1194-1199.
23. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 1998, 352:1725-1730.
24. Moore Rd, Chaisson RE. Natural history of opportunistic disease in an HIV-infected urban clinical cohort. Ann Intern Med 1996, 124:633-642.
25. Hall CD, Dafni U, Simpson D, and the AIDS Clinical Trial Group 243 Team. Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. N Engl J Med 1998, 338:1345-1351.
26. Huang SS, Skolasky RL, Dal Pan GJ, Royal W, McArthur JC. Survival prolongation in HIV-associated progressive multifocal leukoencephalopathy treated with alpha-Interferon. an observational study. J Neurovirol 1998, 4:324-332.
27. Casnault J, Taoufik Y, Abbed K, et al. Experience of cidofovir in HIV-associated progressive multifocal leukoencephalopathy. clinical and virological monitoring. In: Abstracts of the 6th Conference on Retroviruses and Opportunistic Infections. Chicago, 31 January-4 February 1999 (Abstract no. 417).
28. De Luca A, Ammassari A, Cingolani A, Giancola ML, Antinori A. Disease progression and poor survival of AIDS-associated progressive multifocal leukoencephalopathy despite highly active antiretroviral therapy [letter]. AIDS 1998, 12:1937-1938.
29. Conway B, Halliday WC, Brunham RC. Human immunodeficiency virus-associated progressive multifocal leukoencephalopathy. Apparent response to 3′-azido-3′-deoxythymidine. Rev Infect Dis 1990, 12:479-482.
30. Von Einsiedel RW, Fife TD, Aksamit AJ, et al. Progressive multifocal leukoencephalopathy in AIDS, a clinicopathological study and review of the literature. J Neurol 1993, 240:391-406.
31. Berger JR, Levy RM, Flomenhoft D, Dobbs M. Predictive factors for prolonged survival in acquired immunodeficiency syndrome-associated progressive multifocal leukoencephalopathy. Ann Neurol 1998, 44:341-349.